The diagnosis and management of central hypothyroidism in 2018
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index; 5 of the 70 sources its claims cite were checked for support.
Abstract
Central hypothyrodism (CeH) is a hypothyroid state caused by an insufficient stimulation by thyrotropin (TSH) of an otherwise normal thyroid gland. Several advancements, including the recent publication of expert guidelines for CeH diagnosis and management, have been made in recent years thus increasing the clinical awareness on this condition. Here, we reviewed the recent advancements and give expert opinions on critical issues. Indeed, CeH can be the consequence of various disorders affecting either the pituitary gland or the hypothalamus. Recent data enlarged the list of candidate genes for heritable CeH and a genetic origin may be the underlying cause for CeH discovered in pediatric or even adult patients without apparent pituitary lesions. This raises the doubt that the frequency of CeH may be underestimated. CeH is most frequently diagnosed as a consequence of the biochemical assessments in patients with hypothalamic/pituitary lesions. In contrast with primary hypothyroidism, low FT4 with low/normal TSH levels are the biochemical hallmark of CeH, and adequate thyroid hormone replacement leads to the suppression of residual TSH secretion. Thus, CeH often represents a clinical challenge because physicians cannot rely on the use of the ‘reflex TSH strategy’ for screening or therapy monitoring. Nevertheless, in contrast with general assumption, the finding of normal TSH levels may indicate thyroxine under-replacement in CeH patients. The clinical management of CeH is further complicated by the combination with multiple pituitary deficiencies, as the introduction of sex steroids or GH replacements may uncover latent forms of CeH or increase the thyroxine requirements.
Overview
CoChat Summary
TL;DR
Central hypothyroidism (CeH) is caused by insufficient TSH stimulation of an otherwise normal thyroid and is biochemically marked by low free T4 with low/normal TSH, making the reflex TSH strategy unreliable for screening and monitoring. This narrative review summarizes recent genetic, diagnostic, and therapeutic advances, including the 2018 ETA guidelines, and emphasizes L-T4 replacement targeted to FT4 rather than TSH.
Key findings
- CeH incidence was estimated at 1:16,000 to about 1:100,000 in different adult or neonatal hypothyroid populations; prevalence is suspected to be underestimated because acquired forms and genetic cases may be missed. The Dutch diagnostic strategy using total T4, thyroxine-binding globulin, and TSH was more sensitive than strategies based on low total T4 plus normal/low TSH used in Japan and the USA.
- The biochemical hallmark is low FT4 with low or normal TSH; diagnosis cannot be achieved by single TSH measurement, and FT4 has the highest diagnostic sensitivity and specificity. Conditions such as nonthyroidal illness, TSH-inhibiting drugs, thyrotoxicosis-related states, pregnancy-related hypothyroxinemia, and assay interference must be excluded. In CeH patients with normal TSH at diagnosis, lack of TSH suppression during L-T4 may indicate under-replacement.
- Genetic causes have expanded; IGSF1 followed by PROP1 are the genes most frequently accounting for inheritable CeH. Candidate genes include isolated CeH genes (TSHβ, TRHR, TBL1X, IRS4) and multiple pituitary hormone deficiency genes; acquired CeH is mainly due to pituitary macroadenomas, craniopharyngiomas, cranial surgery or irradiation, head trauma, vascular accidents, autoimmune disease, infiltrative lesions, and infections.
- First-line treatment is levothyroxine (L-T4), started after excluding or treating cortisol deficit. Adequacy is evaluated after 6–8 weeks by targeting FT4 above the median of the reference range, then annually; starting doses are 1.0–1.2 μg/kg/day in patients older than 60 years or with cardiovascular comorbidities. Severe congenital CeH should be treated within 2 weeks of birth at 10–12 μg/kg/day, milder congenital forms at 5–10 μg/kg/day, childhood at 3.0–5.0 μg/kg/day, and adolescence at 2.0–2.4 μg/kg/day; pregnancy requires a 20–50% increase and FT4 in the upper quartile. Combined L-T4/L-T3 is not generally supported, though it may be considered in patients with the DIO2 Thr92Ala polymorphism or persistent symptoms despite adequate L-T4.
Methods
- Narrative review and expert opinion synthesizing recent advancements and the 2018 European Thyroid Association guidelines on CeH diagnosis and management.
- No primary data collection, systematic search strategy, inclusion criteria, or meta-analysis is described; the paper presents tables of candidate genes, acquired causes, differential diagnoses, and conditions requiring therapy adjustment.
Limitations
- The paper states that CeH diagnosis and management remain challenging due to lack of accurate clinical and biochemical parameters; recognition of mild or hidden CeH is hampered by the lack of a sufficiently sensitive parameter, and interpretation of diagnostic tests is controversial and resource-dependent.
- The paper states that combined L-T4/L-T3 therapy may carry a higher risk of thyrotoxicosis in CeH because there is no highly reliable parameter to check overtreatment, and studies failing to show benefit may lack power because the DIO2 polymorphism is relatively infrequent.
- Evident from the text: this is a narrative review rather than a systematic evidence synthesis, and some cited evidence includes a prospective study performed on a small number of patients, so selection and reporting bias cannot be excluded.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
5 Valid · 13 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, a progressive onset of the thyrotrope defect beyond the critical neonatal period can be not infrequently seen in several of these genetic CeH cases (3, 9, 28, 30).”
§ The diagnosis and management of central hypothyroidism in 2018 > Clinical presentation
What the sources say
- Not checked yetcites [3] Persani L Bonomi M The multiple genetic causes of central hypothyroidism. Best Practice and Research: Clinical Endocrinology and Metabolism 2017 31 255– 263. (10.1016/j.beem.2017.04.003) 28648512 source
- Partly supportedcites [9] Bonomi M Busnelli M Beck-Peccoz P Costanzo D Antonica F Dolci C Pilotta A Buzi F Persani L. A family with complete resistance to thyrotropin-releasing hormone. New England Journal of Medicine 2009 360 731– 734. (10.1056/NEJMbib808557) 19213692 sourceExperimental — accuracy not yet measured
In “A Family with Complete Resistance to Thyrotropin-Releasing Hormone” (page not provided), the authors report central hypothyroidism in two adult siblings and conclude that thyroid stimulation was not overtly impaired at birth or during infancy. This supports a defect becoming apparent after the neonatal period in this family, but the paper does not establish that onset is progressive or that this occurs not infrequently across several genetic CeH conditions. (LLM, conf=0.83)
- Not checked yetcites [28] Schoenmakers N Alatzoglou KS Chatterjee VK Dattani MT. Recent advances in central congenital hypothyroidism. Journal of Endocrinology 2015 227 R51– R71. (10.1530/JOE-15-0341) 26416826 PMC4629398 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“novel biological drugs inducing hypophysitis such as ipilimumab or other check-point inhibitors (63).”
§ The diagnosis and management of central hypothyroidism in 2018 > Therapeutical management
What the sources say
- Partly supportedcites [63] Ryder M Callahan M Postow MA Wolchok J Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer 2014 21 371– 381. (10.1530/ERC-13-0499) 24610577 PMC4573438 sourceExperimental — accuracy not yet measured
The Results (Hypophysitis; page unavailable) identify hypophysitis in patients treated with ipilimumab, including patients receiving ipilimumab plus the checkpoint inhibitor nivolumab. This supports ipilimumab as an example, but the paper does not establish that other checkpoint inhibitors independently induce hypophysitis. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In fact, there is no evidence from the many studies performed both in adults and in children to support a superiority of this treatment over the sole levothyroxine (66, 67, 68).”
§ The diagnosis and management of central hypothyroidism in 2018 > Therapeutical management
What the sources say
- Not checked yetcites [66] Cassio A Cacciari E Cicognani A Damiani G Missiroli G Corbelli E Balsamo A Bal M Gualandi S. Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine? Pediatrics 2003 111 1055– 1060. (10.1542/peds.111.5.1055) 12728088 source
- Partly supportedcites [67] Wiersinga WM Duntas L Fadeyev V Nygaard B Vanderpump MPJ. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. European Thyroid Journal 2012 1 55– 71. (10.1159/000339444) 24782999 PMC3821467 sourceExperimental — accuracy not yet measured
The Meta-Analysis of RCTs (page unavailable) reports no overall effectiveness difference between combination therapy and L-T4 alone across 11 studies of adults with hypothyroidism. The Synopsis of RCTs likewise finds insufficient evidence of a benefit. Neither passage establishes that studies were performed in children or that the finding applies specifically to central hypothyroidism. (LLM, conf=0.88)
- Not checked yetcites [68] Slawik M Klawitter B Meiser E Schories M Zwermann O Borm K Peper M Lubrich B Hug MJ Nauck M, Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. Journal of Clinical Endocrinology and Metabolism 2007 92 4115– 4122. (10.1210/jc.2007-0297) 17711927 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since the thyroid hormone levels are higher during childhood, higher doses of LT4 are required in children (56).”
§ The diagnosis and management of central hypothyroidism in 2018 > Therapeutical management
What the sources say
- Partly supportedcites [56] Aleksander PE Brückner-Spieler M Stoehr AM Lankes E Kühnen P Schnabel D Ernert A Stäblein W Craig ME Blankenstein O, Mean high-dose l-thyroxine treatment is efficient and safe to achieve a normal IQ in young adult patients with congenital hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2018 103 1459– 1469. (10.1210/jc.2017-01937) 29325045 sourceExperimental — accuracy not yet measured
The Discussion reports that a high initial LT4 dose was needed for optimal cognitive development in patients with congenital hypothyroidism, and that treated patients had elevated T4 during their first two years. It does not establish that thyroid hormone levels are generally higher during childhood than adulthood, or that this is why children require higher LT4 doses. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Mental retardation can be particularly severe in case of delay in the diagnosis of isolated congenital CeH associated with biallelic TSHβ mutations, due to the false-negative results of the neonatal TSH screening for primary thyroid defects (3, 20, 21, 22, 23, 24, 25).”
§ The diagnosis and management of central hypothyroidism in 2018 > Clinical presentation
What the sources say
- Not checked yetcites [3] Persani L Bonomi M The multiple genetic causes of central hypothyroidism. Best Practice and Research: Clinical Endocrinology and Metabolism 2017 31 255– 263. (10.1016/j.beem.2017.04.003) 28648512 source
- Not checked yetcites [20] Libri DV Trettene A Bonomi M Beck-Peccoz P Persani L Salvatoni A The unusual adequate development of a child with severe central hypothyroidsm negative at neonatal thyrotropin screening. Journal of Endocrinological Investigation 2013 36 788– 789. (10.3275/8963) 23665514 doi:10.3275/8963
- Not checked yetcites [21] Ramos HE Labedan I Carré A Castanet M Guemas I Tron E Madhi F Delacourt C Maciel RMB Polak M New cases of isolated congenital central hypothyroidism due to homozygous thyrotropin beta gene mutations: a pitfall to neonatal screening. Thyroid 2010 20 639– 645. (10.1089/thy.2009.0462) 20553196 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims
Create a free account to see all 88 claims and to verify the 64 references still open.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 25
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The diagnosis in three of the four probands with biallelic TRHR mutations was made during childhood because of delayed growth accompanied by lethargy and fatigue or by overweight.”
From Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update—An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology (2021) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In case of untreated adrenal insufficiency, LT4 treatment may cause an adrenal crisis.”
The cited source says what the claim attributes to it.
In the citing paper
“Central CH is more frequently part of MPHD and can be associated with one or more other pituitary hormone deficiences.”
In the citing paper
“In central CH, TSH is usually normal, but can be lower than normal or mildly elevated; only fT4 will contribute to the diagnosis (25,45).”
In the citing paper
“In central CH, TSH is usually normal, but can be lower than normal or mildly elevated; only fT4 will contribute to the diagnosis (25,45).”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Demers, L. M., & Spencer, C. A. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01681.x · Cited by 460
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Central Hypothyroidism: Pathogenic, Diagnostic, and Therapeutic Challenges
Persani, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1616 · Cited by 295
Self-citationRazvi, S., Weaver, J. U., Butler, T. J., & Pearce, S. H. S. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.1159 · Cited by 266
Beck-Peccoz, P., Amr, S., Menezes-Ferreira, M. M., Faglia, G., & Weintraub, B. D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198504253121703 · Cited by 261
Jostel, A., Ryder, W. D. J., & Shalet, S. M. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03534.x · Cited by 238
Persani, L., Brabant, G., Dattani, M., Bonomi, M., Feldt-Rasmussen, U., Fliers, E., Gruters, A., Maiter, D., Schoenmakers, N., & van Trotsenburg, A. S. P. (2018) · European Thyroid Journal · doi:10.1159/000491388 · Cited by 222
Self-citation
Research works printed but not linked: 70
- 2008, Mechanisms related to the pathophysiology and management of central hypothyroidism, Nature Clinical Practice: Endocrinology and Metabolism, 4, 683
- Klose M Marina D Hartoft-Nielsen ML Klefter O Gavan V Hilsted L Rasmussen AK Feldt-Rasmussen U. Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2013 98 3802– 3810. (10.1210/jc.2013-1610) 23796569 · DOI · Paper page
- LaFranchiSH, screening strategies for congenital hypothyroidism an update of Disease https org, Journal Inherited Metabolic, 201033, 10.1007/s10545-010-9062-1 · DOI · Paper page
- Persani L Tonacchera M Beck-Peccoz P Vitti P Mammoli C Chiovato L Elisei R Faglia G Ludgate M Vassart G Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. Journal of Endocrinological Investigation 1993 16 511– 519. (10.1007/BF03348894) 8227980 · DOI · Paper page
- Koch CA Sarlis NJ. The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management. Journal of Endocrinological Investigation 2001 24 659– 675. (10.1007/BF03343911) 11716153 · DOI · Paper page
- Pfäffle R Klammt J Pituitary transcription factors in the aetiology of combined pituitary hormone deficiency. Best Practice and Research. Clinical Endocrinology and Metabolism 2011 25 43– 60. (10.1016/j.beem.2010.10.014) 21396574 · DOI · Paper page
- Jonklaas J Bianco AC Bauer AJ Burman KD Cappola AR Celi FS Cooper DS Kim BW Peeters RP Rosenthal MS, Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 2014 24 1670– 1751. (10.1089/thy.2014.0028) 25266247 PMC4267409 · DOI · Paper page
- 2012, Mass screening of newborns for congenital hypothyroidism of central origin by free thyroxine measurement of blood samples on filter paper, European Journal of Endocrinology, 166, 829, 10.1530/eje-11-0653 · DOI · Paper page
- Recent advances in central congenital hypothyroidism of https org, Journal Endocrinology, 51
- 2012, Clinical review: entral hypothyroidism: pathogenic, diagnostic, and therapeutic challenges, Journal of Clinical Endocrinology and Metabolism, 97, 3068, 10.1210/jc.2012-1616 · DOI · Paper page
- Panicker V Saravanan P Vaidya B Evans J Hattersley AT Frayling TM Dayan CM. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology and Metabolism 2009 94 1623– 1629. (10.1210/jc.2008-1301) 19190113 · DOI · Paper page
- 1999, Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism, Journal of Clinical Endocrinology and Metabolism, 84, 924
- Appelhof BC Peeters RP Wiersinga WM Visser TJ Wekking EM Huyser J Schene AH Tijssen JGP Hoogendijk WJG Fliers E. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. Journal of Clinical Endocrinology and Metabolism 2005 90 6296– 6299. (10.1210/jc.2005-0451) 16144953 · DOI · Paper page
- Atmaca H Tanriverdi F Gokce C Unluhizarci K Kelestimur F. Do we still need the TRH stimulation test? Thyroid 2007 17 529– 533. (10.1089/thy.2006.0311) 17614773 · DOI · Paper page
- Benvenga S Capodicasa G Perelli S. L-thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism. Frontiers in Endocrinology 2017 8 321 (10.3389/fendo.2017.00321) 29209276 PMC5701926 · DOI · Paper page
- 1994, Variable biological activity of thyroid-stimulating hormone, European Journal of Endocrinology, 131, 331, 10.1530/eje.0.1310331 · DOI · Paper page
- Alexopoulou O Beguin C De P Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. European Journal of Endocrinology 2004 150 1– 8. (10.1530/eje.0.1500001) 14713273 · DOI · Paper page
- 2012, Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality, Archives of Internal Medicine, 172, 811
- Persani L Beck-Peccoz P. Central hypothyroidism. In Werner and Ingbar’s the Thyroid: A Fundamental and Clinical Text, 10th ed., Chapter 38, pp 560– 568. Eds Braverman L & Cooper D Philadelphia, PA, USA: Lippincott Williams & Wilkins/Wolters Kluwer Health, 2012.
- Ryder M Callahan M Postow MA Wolchok J Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer 2014 21 371– 381. (10.1530/ERC-13-0499) 24610577 PMC4573438 · DOI · Paper page
- 2013, The unusual adequate development of a child with severe central hypothyroidsm negative at neonatal thyrotropin screening, Journal of Endocrinological Investigation, 36, 788
- Demers LM Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clinical Endocrinology 2003 58 138– 140. (10.1046/j.1365-2265.2003.01681.x) 12580927 · DOI · Paper page
- Rose SR Cranial irradiation and central hypothyroidism. Trends in Endocrinology and Metabolism 2001 12 97– 104. (10.1016/S1043-2760(00)00359-3) 11306333 · DOI · Paper page
- Joustra SD Heinen CA Schoenmakers N Bonomi M Ballieux BEPB Turgeon M-O Bernard DJ Fliers E Trotsenburg ASP van Losekoot M, IGSF1 deficiency: lessons from an extensive case series and recommendations for clinical management. Journal of Clinical Endocrinology and Metabolism 2016 101 1627– 1636. (10.1210/jc.2015-3880) 26840047 PMC4880178 · DOI · Paper page
- Wiersinga WM Duntas L Fadeyev V Nygaard B Vanderpump MPJ. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. European Thyroid Journal 2012 1 55– 71. (10.1159/000339444) 24782999 PMC3821467 · DOI · Paper page
- 1979, Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin, Journal of Clinical Endocrinology and Metabolism, 48, 989, 10.1210/jcem-48-6-989 · DOI · Paper page
- 2001, Hyperplastic pituitary gland, high serum glycoprotein hormone alpha-subunit, and variable circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene, Journal of Clinical Endocrinology and Metabolism, 86, 1600
- Hayashizaki Y Hiraoka Y Endo Y Miyai K Matsubara K Thyroid-stimulating hormone (TSH) deficiency caused by a single base substitution in the CAGYC region of the beta-subunit. EMBO Journal 1989 8 2291– 2296. (10.1002/j.1460-2075.1989.tb08355.x) 2792087 PMC401161 · DOI · Paper page
- 1985, Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone, New England Journal of Medicine, 312, 1085, 10.1056/nejm198504253121703 · DOI · Paper page
- Jostel A Ryder WDJ Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH Index. Clinical Endocrinology 2009 71 529– 534. (10.1111/j.1365-2265.2009.03534.x) 19226261 · DOI · Paper page
- 2018, A novel IGSF1 mutation in a large Irish kindred highlights the need for familial screening in the IGSF1 deficiency syndrome, Clinical Endocrinology, 89, 813, 10.1111/cen.13827 · DOI · Paper page
- 2010, Newborn screening results in children with central hypothyroidism, Journal of Pediatrics, 156, 990, 10.1016/j.jpeds.2009.12.011 · DOI · Paper page
- 2016, Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients, Endocrine, 54, 15, 10.1007/s12020-016-1047-x · DOI · Paper page
- Benaglia L Busnelli A Somigliana E Leonardi M Vannucchi G De S Fugazzola L Ragni G Fedele L. Incidence of elevation of serum thyroid-stimulating hormone during controlled ovarian hyperstimulation for in vitro fertilization. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2014 173 53– 57. (10.1016/j.ejogrb.2013.11.003) 24332278 · DOI · Paper page
- Refetoff S Bassett JH Beck-Peccoz P Bernal J Brent G Chatterjee K De Groot LJ Dumitrescu AM Jameson JL Kopp PA, et al Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. European Thyroid Journal 2014 3 7– 9. (10.1159/000358180) 24847459 PMC4005262 · DOI · Paper page
- Shimon I Cohen O Lubetsky A Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 2002 12 823– 827. (10.1089/105072502760339406) 12481949 · DOI · Paper page
- Doin FC Rosa-Borges M Martins MRA Moisés VA Abucham J. Diagnosis of subclinical central hypothyroidism in patients with hypothalamic–pituitary disease by Doppler echocardiography. European Journal of Endocrinology 2012 166 631– 640. (10.1530/EJE-11-0907) 22267279 · DOI · Paper page
- Mechanisms in an update in the genetic aetiologies of combined pituitary hormone deficiency of https org, Endocrinology European Journal Endocrinology, 2016174, 10.1530/eje-15-1095 · DOI · Paper page
- 2018, 2018 European Thyroid Association (ETA) guidelines on the diagnosis and management of central hypothyroidism, European Thyroid Journal, 7, 225, 10.1159/000491388 · DOI · Paper page
- 2001, Screening for central hypothyroidism is unjustified, BMJ, 322, 798, 10.1136/bmj.322.7289.798 · DOI · Paper page
- Pappa T Johannesen J Scherberg N Torrent M Dumitrescu A Refetoff SA. TSHβ variant with impaired immunoreactivity but intact biological activity and its clinical implications. Thyroid 2015 25 869– 876. (10.1089/thy.2015.0096) 25950606 PMC4533086 · DOI · Paper page
- 2010, New cases of isolated congenital central hypothyroidism due to homozygous thyrotropin beta gene mutations: a pitfall to neonatal screening, Thyroid, 20, 639, 10.1089/thy.2009.0462 · DOI · Paper page
- Cassio A Cacciari E Cicognani A Damiani G Missiroli G Corbelli E Balsamo A Bal M Gualandi S. Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine? Pediatrics 2003 111 1055– 1060. (10.1542/peds.111.5.1055) 12728088 · DOI · Paper page
- 2016, Mutations in TBL1X are associated with central hypothyroidism, Journal of Clinical Endocrinology and Metabolism, 101, 4564, 10.1210/jc.2016-2531 · DOI · Paper page
- Aleksander PE Brückner-Spieler M Stoehr AM Lankes E Kühnen P Schnabel D Ernert A Stäblein W Craig ME Blankenstein O, Mean high-dose l-thyroxine treatment is efficient and safe to achieve a normal IQ in young adult patients with congenital hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2018 103 1459– 1469. (10.1210/jc.2017-01937) 29325045 · DOI · Paper page
- 2017, Central hypothyroidism – a neglected thyroid disorder, Nature Reviews Endocrinology, 13, 588, 10.1038/nrendo.2017.47 · DOI · Paper page
- Portes ES Oliveira JH MacCagnan P Abucham J. Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children. Clinical Endocrinology 2000 53 183– 189. (10.1046/j.1365-2265.2000.01071.x) 10931099 · DOI · Paper page
- 2007, Interactions between growth hormone and the thyroid gland – with special reference to biochemical diagnosis, Current Medicinal Chemistry, 14, 2783, 10.2174/092986707782360114 · DOI · Paper page
- 2017, The multiple genetic causes of central hypothyroidism, Best Practice and Research: Clinical Endocrinology and Metabolism, 31, 255, 10.1016/j.beem.2017.04.003 · DOI · Paper page
- 2006, Neonatal screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine-binding globulin measurement: potentials and pitfalls, Journal of Clinical Endocrinology and Metabolism, 91, 3370, 10.1210/jc.2006-0058 · DOI · Paper page
- 1995, Bioactivity of thyrotropin (TSH) in patients with central hypothyroidism: comparison between in vivo 3,5,3′-triiodothyronine response to TSH and in vitro bioactivity of TSH, Journal of Clinical Endocrinology and Metabolism, 80, 1124
- Genetic overlap in Kallmann syndrome combined pituitary hormone deficiency and septo - optic dysplasia of and https org, Journal Clinical Endocrinology Metabolism, 201297, 10.1210/jc.2011-2938 · DOI · Paper page
- 1997, A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene, Journal of Clinical Endocrinology and Metabolism, 82, 1561
- 1971, Familial isolated thyrotropin deficiency with cretinism, New England Journal of Medicine, 285, 1043, 10.1056/nejm197111042851902 · DOI · Paper page
- 2013, The IGSF1 deficiency syndrome: characteristics of male and female patients, Journal of Clinical Endocrinology and Metabolism, 98, 4942, 10.1210/jc.2013-2743 · DOI · Paper page
- 1990, Familial hypothyroidism caused by a nonsense mutation in the thyroid-stimulating hormone beta-subunit gene, American Journal of Human Genetics, 46, 988
- Feldt-Rasmussen U Klose M Benvenga S. Interactions between hypothalamic pituitary thyroid axis and other pituitary dysfunctions. Endocrine 2018 62 519– 527. (10.1007/s12020-018-1738-6) 30191443 · DOI · Paper page
- Bianco AC Casula S. Thyroid hormone replacement therapy: three ‘simple’ questions, complex answers. European Thyroid Journal 2012 1 88– 98. (10.1159/000339447) 24783002 PMC3821470 · DOI · Paper page
- 2012, Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement, Nature Genetics, 44, 1375, 10.1038/ng.2453 · DOI · Paper page
- Yamakita N Komaki T Takao T Murai T Hashimoto K Yasuda K. Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion. Journal of Clinical Endocrinology and Metabolism 2001 86 1054– 1060. (10.1210/jcem.86.3.7267) 11238485 · doi:10.1210/jcem.86.3.7267 · Paper page
- 2000, Circulating thyrotropin bioactivity in sporadic central hypothyroidism, Journal of Clinical Endocrinology and Metabolism, 85, 3631
- 2018, Mutations in IRS4 are associated with central hypothyroidism, Journal of Medical Genetics, 55, 693, 10.1136/jmedgenet-2017-105113 · DOI · Paper page
- 2011, What should be done when thyroid function tests do not make sense?, Clinical Endocrinology, 74, 673, 10.1111/j.1365-2265.2011.04023.x · DOI · Paper page
- 2012, Central hypothyroidism, Werner and Ingbar’s the Thyroid: A Fundamental and Clinical Text, 560
- Slawik M Klawitter B Meiser E Schories M Zwermann O Borm K Peper M Lubrich B Hug MJ Nauck M, Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. Journal of Clinical Endocrinology and Metabolism 2007 92 4115– 4122. (10.1210/jc.2007-0297) 17711927 · DOI · Paper page
- Faglia G. The clinical impact of the thyrotropin-releasing hormone test. Thyroid 1998 8 903– 908. (10.1089/thy.1998.8.903) 9827657 · DOI · Paper page
- 2011, Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine, Clinical Endocrinology, 74, 744, 10.1111/j.1365-2265.2011.03984.x · DOI · Paper page
- 1971, Effect of thyrotropin-releasing factor on serum thyroid-stimulating hormone. An approach to distinguishing hypothalamic from pituitary forms of idiopathic hypopituitary dwarfism, Journal of Clinical Investigation, 50, 2219, 10.1172/jci106717 · DOI · Paper page
- Hartoft-Nielsen ML Lange M Rasmussen AK Scherer S Zimmermann-Belsing T Feldt-Rasmussen U. Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology. Hormone Research 2004 61 53– 57. (10.1159/000075239) 14646390 · DOI · Paper page
- 2009, A family with complete resistance to thyrotropin-releasing hormone, New England Journal of Medicine, 360, 731, 10.1056/nejmc0808557 · DOI · Paper page
Cited by
van Trotsenburg, P., Stoupa, A., Léger, J., Rohrer, T., Peters, C., Fugazzola, L., Cassio, A., Heinrichs, C., Beauloye, V., Pohlenz, J., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0333 · Cited by 469
“To date, defective thyrotropin-releasing hormone (TRH) action due to biallelic mutations in the TRHR gene has been described in only a few families (45).”
BackgroundInfluentialSelf-citationInsights into non-classic and emerging causes of hypopituitarism
Prodam, F., Caputo, M., Mele, C., Marzullo, P., & Aimaretti, G. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00437-2 · Cited by 71
New genetics in congenital hypothyroidism
Stoupa, A., Kariyawasam, D., Muzza, M., de Filippis, T., Fugazzola, L., Polak, M., Persani, L., & Carré, A. (2021) · Endocrine · doi:10.1007/s12020-021-02646-9 · Cited by 59
“In addition, a certain percentage of affected patients have morphological abnormalities of the pituitary gland or hypothalamus, or other neurological defects [21, 22].”
BackgroundSelf-citationGenetics of congenital hypothyroidism: Modern concepts
Stoupa, A., Kariyawasam, D., Polak, M., & Carré, A. (2022) · Pediatric Investigation · doi:10.1002/ped4.12324 · Cited by 58
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Belaya, Z. E., Danilov, N. M., Elfimova, E. M., Litvin, A. Y., Rozhinskaya, L. Y., Sviridenko, N. Y., Швецов, М. Ю., et al. (2023) · Eurasian heart journal · doi:10.38109/2225-1685-2023-1-6-65 · Cited by 35
Roche, E. F., McGowan, A., Koulouri, O., Turgeon, M., Nicholas, A. K., Heffernan, E., El‐Khairi, R., Abid, N., Lyons, G., Halsall, D., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13827 · Cited by 29
Self-citationThyroid hormone resistance: mechanisms and therapeutic development
Yao, B., Yang, C., Pan, C., & Li, Y. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111679 · Cited by 26
Fitzgerald, S. P., & Falhammar, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920854 · Cited by 20
“The measurement of FT4 levels rather than TSH levels as well as being a better general test for euthyroidism also covers the possibility of secondary thyroid dysfunction that might be missed with screening TSH testing (57).”
BackgroundThe Laboratory Features of Congenital Hypothyroidism and Approach to Therapy
Weiner, A., Oberfield, S. E., & Vuguin, P. M. (2020) · NeoReviews · doi:10.1542/neo.21-1-e37 · Cited by 16
Wang, F., Han, J., Shang, X., & Li, G. (2019) · BMC Pediatrics · doi:10.1186/s12887-019-1819-6 · Cited by 15
Draft of the clinical recommendations for diagnosis and treatment of hypothyroidism
Fadeev, V. V., Моргунова, Т. Б., Mel'nichenko, G. A., & Dedov, I. I. (2021) · Clinical and experimental thyroidology · doi:10.14341/ket12702 · Cited by 16
Refractory hypothyroidism: unraveling the complexities of diagnosis and management
Quiroz-Aldave, J. E., Concepción-Zavaleta, M. J., Durand-Vásquez, M. D. C., Concepción-Urteaga, L. A., Gamarra-Osorio, E. R., Suárez-Rojas, J., Rafael-Robles, L. D. P., Paz-Ibarra, J., & Román-González, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.09.003 · Cited by 14
Acar, S., Gürsoy, S., Arslan, G., Nalbantoğlu, Ö., Hazan, F., Köprülü, Ö., Özkaya, B., & Özkan, B. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01706-1 · Cited by 13
“Various genetic causes have been associated with central CH: TSHB, IGSF1, TRHR, and TBLX1 [6, 7].”
BackgroundDoes Early Identification of Central Congenital Hypothyroidism Result in Improved Outcomes?
Donaldson, M., & Grosse, S. D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab059 · Cited by 13
“However, although central CH is less common than primary CH, with an incidence of 1 in 16 000 to 1 in 30 000 in recent publications (4), it is similar in magnitude to that of many other disorders that are widely screened, such as phenylketonuria, congenital adrenal hyperplasia, and mediumchain acyl-CoA dehydrogenase d…”
BackgroundApproach to the Patient With Congenital Hypothyroidism
Stoupa, A., Kariyawasam, D., Quoc, A. N., Polak, M., & Carré, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac534 · Cited by 14
The Consensus on the Diagnosis and Management of Congenital Hypothyroidism in Term Neonates
Hashemipour, M., Rabbani, A., Rad, A. H., & Dalili, S. (2023) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_535_21 · Cited by 12
“The prevalence of primary congenital hypothyroidism and central hypothyroidism is 1 in 3000–4000 and 1 in 11000– 100000 live births, respectively.[8] In Iran, the prevalence of primary congenital Address for correspondence: Dr.”
BackgroundMulti-omic profiling of pituitary thyrotropic cells and progenitors
Daly, A. Z., Dudley, L. A., Peel, M. T., Liebhaber, S. A., Parker, S. C. J., & Camper, S. A. (2021) · BMC Biology · doi:10.1186/s12915-021-01009-0 · Cited by 10
“The incidence of secondary hypothyroidism is estimated to be 1:20,000 to 1:80,000 individuals [10].”
BackgroundInsulin Resistance and Glucose Metabolism during Infection
Arneth, B. M. (2023) · Endocrines · doi:10.3390/endocrines4040049 · Cited by 8
Iglesias, P. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.004 · Cited by 8
van Trotsenburg, A. S. P., Stoupa, A., Léger, J., Rohrer, T. R., Peters, C. J., Fugazzola, L., Cassio, A., Heinrichs, C., Beauloye, V., Pohlenz, J., et al. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.3.8 · Cited by 9
Self-citationGénétique de l’hypothyroïdie congénitale
Stoupa, A., Kariyawasam, D., Polak, M., & Carré, A. (2022) · médecine/sciences · doi:10.1051/medsci/2022028 · Cited by 7
Gavryutina, I., Fordjour, L., & Chin, V. L. (2022) · Endocrines · doi:10.3390/endocrines3020018 · Cited by 8
Castets, S., Albarel, F., Bachelot, A., Brun, G., Bouligand, J., Briet, C., Quoc, E. B., Cazabat, L., Chabbert‐Buffet, N., Christin‐Maître, S., et al. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.03.001 · Cited by 6
Patyra, K., Makkonen, K., Haanpää, M. K., Karppinen, S., Viikari, L. A., Toppari, J., Reeve, M. P., & Kero, J. T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.658137 · Cited by 7
“Reduced stimulation can result either from an impaired secretion of thyroid stimulating hormone (TSH) from the anterior pituitary, defective secretion or action of hypothalamic thyrotropin releasing hormone (TRH), or both (1).”
BackgroundDiagnosis and Management of Neuroendocrine Disorders of Survivors of Brain Tumors
Erickson, D. Z., & Donegan, D. M. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321059 · Cited by 6
Chaker, L., & Peeters, R. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00015-9 · Cited by 9
Subclinical central hypothyroidism in patients with hypothalamic-pituitary disease: does it exist?
Abucham, J., & Martins, M. R. A. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09876-y · Cited by 5
“The most common causes of CH in newborns and infants are inherit-able conditions [19].”
Guo, L. Z. (2021) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2021.112005 · Cited by 5
“The hypothesis behind the purpose of the TSHβ variant is to reduce T3/T4 production either by negative feedback on pituitary-made TSH or some other form of disruption [21].”
BackgroundToi, N., Kurajoh, M., Miyaoka, D., Nagata, Y., Yamada, S., Imanishi, Y., Hayashi, D., Tateishi, C., Inaba, M., Tsuruta, D., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0313 · Cited by 5
“TRH stimulation test During the follow-up period, TRH stimulation testing was performed, with patients diagnosed with CH based on combined findings of low or low-normal F-T4 with an inappropriately low or normal TSH level [18, 19].”
MethodCentral hypothyroidism and cardiovascular disease: a Spanish cohort observational study
Guerrero‐Pérez, F., Iglesias, P., Fano, M. P., Rodríguez, M. D. M., Biagetti, B., Cordido, F., Novoa-Testa, I., García-Centeno, R., Fernández, L. G., Araujo-Castro, M., et al. (2025) · HORMONES · doi:10.1007/s42000-025-00707-6 · Cited by 4
“…due to TSH or TRH (among other hypothalamic or pituitary factors) gene mutation that produce isolated CeH or multiple pituitary hormone de�ciencies [1], but most frequently is caused by acquired anatomical conditions that affect hypothalamus and/or the pituitary gland such as tumors, surgical…”
Ghemigian, A. M., & Dumitru, N. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005825 · Cited by 4
Unveiling the hidden: acquired pediatric hypothyroidism
Salerno, M., Capalbo, D., Valenzise, M., Mase, R. D., Morabito, L. A., Centonze, C., & Wasniewska, M. G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1744280 · Cited by 4
Cognitive Dysfunction in Hypothyroidism
Rakugi, H. (2023) · Science Insights · doi:10.15354/si.23.re126 · Cited by 4
“Moreover, people with pituitary stalk interruption syndrome (PSIS) can get central hypothyroidism early in life, but they usually have slow growth and/or low sexual development, and their cognitive function is not significantly affected (53, 54).”
BackgroundCentral hypothyroidism or subclinical hyperthyroidism: can they be confused with each other?
Boronat, M. (2020) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-20-0059 · Cited by 3
Kardelen, A. D., Özturan, E. K., Poyrazoğlu, Ş., Baş, F., Ceylaner, S., Joustra, S. D., Wit, J. M., & Darendelıler, F. (2023) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2022.2021-12-3 · Cited by 2
“The combination of CeH and prolactin deficiency are particularly suspicious for IGSF1 deficiency, but are also observed in TRH receptor variants and may be a part of multiple hormone deficiency caused by a variant in POU1F1, PROP1, HESX1 or LHX3 (18).”
BackgroundRyzhkova, E. G., & Ladygina, D. O. (2022) · Problems of Endocrinology · doi:10.14341/probl13128 · Cited by 2
Castinetti, F., Albarel, F., Cuny, T., Morange, I., Vermalle, M., & Brue, T. C. (2024) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(24)49086-7 · Cited by 2
Zheng, X.-T., Lin, X., Ma, M., Lai, S., & Yang, C. (2024) · HORMONES · doi:10.1007/s42000-024-00547-w · Cited by 2
“Once central or primary hypothyroidism is diagnosed, levothyroxine (LT4) treatment is initiated after intact adre - nal function is observed or after glucocorticoid treatment has been started [2 ].”
Huang, R., Zou, F.-L., Li, M.-J., Wu, Q., Yang, Q., Tang, B.-Z., & Liang, X. (2021) · PubMed · doi:10.7499/j.issn.1008-8830.2106051 · Cited by 3
Boggiano, V. L., Barnhouse, K., Rodriguez, T. G., & Kim, L. (2023) · BMJ Case Reports · doi:10.1136/bcr-2023-256177 · Cited by 1
Owolabi, M., Malone, M. A., & Merritt, A. (2024) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2024.04.004 · Cited by 1
Refractory hypothyroidism in children: an overview
Metwalley, K. A., & Farghaly, H. S. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0306 · Cited by 2
“Sustaining FT4 in the upper half of the age-appropriate reference range is the aim of treatment for CeH [9].”
Matusiak, A. E., Stępniak, J., Lewandowski, K. C., Lewiñski, A., & Karbownik‐Lewińska, M. (2025) · Metabolites · doi:10.3390/metabo15020125 · Cited by 1
“The prevalence of central hypothyroidism has been estimated to range from 1:16,000 to approximately 1:100,000 [3].”
Geremia, C., & Geremia, F. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0082 · Cited by 1
Köprülü, Ö., Acar, S., Uzman, C. Y., Erbaş, İ. M., Nalbantoğlu, Ö., Hazan, F., Gürsoy, S., Korkmaz, H. A., & Özkan, B. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0119 · Cited by 1
“[6 ].”
Approach to the patient: genetics and management of congenital hypothyroidism
Quoc, A. N., Kariyawasam, D., Polak, M., Carré, A., & Stoupa, A. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag215 · Cited by 1
Samec, B., Setnikar, G., Gaberšček, S., & Kocjan, T. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1543-8826 · Cited by 1
Álvarez, M., & Rosero, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88859 · Cited by 1
Attia, A. I. M. M., Atef, A., Badawi, N. E., Abdou, M., Yassin, S., Helmy, E., & Ibrahim, H. A. A. (2022) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2022.9060 · Cited by 1
Методы хирургического лечения многоузлового зоба у пациентов в йододефицитном регионе
Магомедов, М. М., & Османов, О. М. (2021) · Естественные и Технические Науки · doi:10.37882/2223-2966.2021.02.16
EXPERIMENTAL ANIMAL MODELS USED IN HYPOTHYROIDISM - OVERVIEW
(2023) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2023/12.5.7163
Castinetti, F., Albarel, F., Cuny, T., Morange, I., Vermalle, M., & Brue, T. C. (2024) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(24)49205-x
Köprülü, Ö., & Tozkır, H. (2025) · Molecular Syndromology · doi:10.1159/000543796
“This impairment of central thyroid stimulation can result from functional or anatomical disorder of hypothalamus or pituitary [1].”
Development and validation of long-acting recombinant human TSH using SAFA technology
Kim, D., Kang, M. J., Lee, S. J., Cho, Y. H., Guo, Z., An, J., Park, J., Han, J., Chi, S., Cha, S.-H., et al. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0284
Tan, H., Liu, Y., & Cholekho, S. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1005432
Diagnostic Challenges: A Review of Non Classic Thyroid Function Test Patterns
Varadaraj, P., & Panchagnula, R. (2025) · National Journal of Laboratory Medicine · doi:10.7860/njlm/2025/73696.2899
Casiraghi, A., Cattoni, A., & Persani, L. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02659-5
“Due to its underhand or indolent presentation, clinicians should be trained to identify early signs of this condition, in order to prevent survivors from experiencing long-lasting untreated symptoms and comorbidities.”
Self-citationAdditional file 2 of Multi-omic profiling of pituitary thyrotropic cells and progenitors
Daly, A. Z., Dudley, L. A., Peel, M. T., Liebhaber, S. A., Parker, S. C. J., & Camper, S. A. (2021) · Figshare · doi:10.6084/m9.figshare.14429507
Additional file 1 of Multi-omic profiling of pituitary thyrotropic cells and progenitors
Daly, A. Z., Dudley, L. A., Peel, M. T., Liebhaber, S. A., Parker, S. C. J., & Camper, S. A. (2021) · Figshare · doi:10.6084/m9.figshare.14429504
Makhieva, Z. K., Анатольевна, К. З., Vasilyeva, E. V., Guchinova, L. A., Taov, M. Z., Sageeva, S. V., Emuzov, S. A., Ibragimova, S. M., Khanzaeva, R. K., Abazova, D. T., et al. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2025-70-9-10-54-61
Gensure, R. C. (2025) · Directory of Open access Books (OAPEN Foundation)
New molecular insights in pathogenesis of congenital hypothyroidism
Stoupa, A. (2021) · theses.fr (ABES) · doi:10.70675/ba72d900z86edz4200z8ddcz1af6c6d513ae
Coexisting ADAR and TSHB Mutations in an Infant With Retinal Detachment and Transient Cardiomyopathy
Draidi, T., Khalil, M., Kabaha, A. A. R., Zuriqi, R., & Masu’d, M. (2026) · Case Reports in Endocrinology · doi:10.1155/crie/5534847
Saheki, T., Harada, E., Yoshimura, T., Kobayashi, T., Fukunaga, K., Imachi, H., & Murao, K. (2026) · Internal Medicine · doi:10.2169/internalmedicine.7555-26
Sunday, E. G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1934568
“Consequently, hydrocephalus-induced hypothalamic suppression could trigger a secondary, systemic hypothyroid state that directly exacerbates glymphatic stasis and delays parenchymal recovery (10, 13 – 16).”
Pan-Hypopituitarism Secondary to Sheehan’s Syndrome: A Case Report and Review of the Literature
OHENHEN, O., & OHENHEN, V. (2026) · Nigerian Journal of Medical and Dental Education
Yambay, C. F. P., & Ruiz, N. A. L. (2025) · Polo del Conocimiento · doi:10.23857/pc.v9i12.8764
Amer, B., Haidarah, A., Alam, A., & Kamrul-Hasan, A. B. M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.09.118
Mata-Salgado, D., Morales-Suárez, J. J., Reza‐Albarrán, A., Hernández-Ramírez, R., Corza-Ayala, M. A., Cienfuegos-Alvear, J. A., González-Jaimes, A. M., Martínez-Duncker, I., & Aláez‐Verson, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1891019
“In contrast, patients with RTH a exhibit distinctive clinical features, together with fT3 and TT3 concentrations at the upper end of the reference range, which may help differentiate RTH a from central hypothyroidism (46).”
Хусеиновна, М. З., Анатольевна, К. З., Андреевна, В. Е., Асланбековна, Г. Л., Заурович, Т. М., Вадимовна, С. С., Анзорович, Е. С., Майрсултановна, И. С., Хаважевна, Х. Р., Abazova, D. T., et al. (n.d.) · CyberLeninK (CyberLeninka)
Metadata
- Authors
- Persani, L., Cangiano, B., & Bonomi, M.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Persani, Luca
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2019-02
- Volume
- 8
- Issue
- 2
- Pages
- R44-R54
- ISSN
- 2049-3614 (ISSN-L)
- PMC
- PMC6373625
- OpenAlex
- W2910846975
- Semantic Scholar
- 9ec81e2746f5485b0787533ee9872d104c56d9b3
- Cited by
- 64
- References
- 73
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 7 · 2022: 10 · 2021: 16 · 2020: 5 · 2019: 2
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Endocrine Connections (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Istituto Auxologico Italiano
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- central hypothyroidism, thyroid-stimulating hormone, pituitary disorders, hypothalamic disorders, candidate genes, thyroid hormone replacement, TSH suppression, growth hormone replacement therapy, pediatric hypothyroidism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.